华立股份公告称，公司于2025年10月30日拟现金收购中科汇联现有股东持有的51%股份并签署意向性协 议。自交易启动，公司积极推进前期尽调并履行信披义务，但交易各方未就核心条款达成共识，公司近 期收到标的公司股东终止收购意向的《函》。经审慎研究，公司决定终止本次收购。协议终止系双方协 商一致，无违约追责情形，对公司生产经营、财务状况无重大不利影响。 ...

Group 1 - The core viewpoint of the article is that Huali Co., Ltd. (603038) has a small portion of its revenue coming from overseas business, specifically indicating that about 10% of its main business revenue is derived from international operations in 2024 [1] - The company has a minor export business to EU countries, which constitutes a relatively small share of its overall operations [1] - The information was provided in response to investor inquiries on the company's interactive platform [1]

1．案件所处的诉讼阶段：法院已开庭审理，原告撤诉 2．上市公司所处的当事人地位：公司、控股子公司福建尚润投资管理有限 公司作为被告方。 证券代码：603038 证券简称：华立股份 公告编号：2025-067 东莞市华立实业股份有限公司 关于公司及控股子公司诉讼事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 特别提示： 公司近日收到淄博市周村区人民法院出具的民事裁定书(2025)鲁 0306 民初 2973 号。具体情况如下： 原告：淄博金财公有资产经营有限公司 被告 1：福建尚润投资管理有限公司 3．涉案金额：(2025)鲁 0306 民初 2973 号诉讼涉案金额为 8,527.08 万元及 相关诉讼费用。 4．是否会对上市公司损益产生负面影响：截至本公告披露日，(2025)鲁 0306 民初 2973 号诉讼原告已撤诉，对公司本期利润或期后利润不构成影响。 一、基本情况 东莞市华立实业股份有限公司（以下简称"公司"）于 2025 年 8 月 16 日披 露公司及控股子公司福建尚润投资管理有限公司（以下 ...

华立股份晚间公告，公司及控股子公司尚润资本作为被告的诉讼案件中，原告淄博金财公有资产经营有 限公司已撤诉。该诉讼涉案金额为8527.08万元及相关诉讼费用。法院裁定准许原告撤诉，案件受理费 和财产保全费共计5025元由原告负担。此诉讼的撤诉不会对公司本期利润或期后利润产生影响。 ...

分组1 - Weili Medical plans to distribute a cash dividend of 2 yuan per 10 shares to all shareholders, based on an undistributed profit of 704 million yuan as of September 30, 2025 [1] - Tongding Interconnect's shareholder plans to reduce their stake by up to 0.49%, equating to a maximum of 605,800 shares [1] - Caitong Securities has received approval from the China Securities Regulatory Commission to issue short-term corporate bonds with a total face value of up to 5 billion yuan [1] 分组2 - Youfu Food intends to use 70 million yuan of its own funds to invest in wealth management products with expected annual returns of up to 4.2% [3] - Keres received an administrative regulatory decision from the Guangdong Securities Regulatory Bureau for violations related to accounts receivable aging calculations and related party transactions [5] - Ouma Software's controlling shareholder has completed the transfer of state-owned equity, changing the controlling shareholder to Shandong Guotou [7] 分组3 - ST Huapeng's wholly-owned subsidiary has completed a major overhaul project and is now in production [8] - Beiqi Blue Valley has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [8] - Weijie Chuangxin received a government subsidy of 5 million yuan, accounting for 21.07% of its projected net profit for 2024 [9] 分组4 - China Resources Double Crane's subsidiary has received a drug registration certificate for a hypertension treatment drug [11] - Huafeng shares are continuing to suspend trading due to a planned change in control [13] - Kaifa Electric's shareholder plans to transfer 36.6869 million shares, representing 11.63% of the total share capital [14] 分组5 - Heng Rui Medicine has received approval for two clinical trials for innovative anti-tumor drugs [15] - Kosen Technology plans to invest 30 million USD to establish a new production base in Malaysia [17] - Sanxing Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 107 million yuan [18] 分组6 - Sitai Li's subsidiary has received a drug registration certificate for a contrast agent used in MRI [21] - Daren Tang's subsidiary has received a drug registration certificate for a pain relief gel [22] - Saike Xide has received approval for three medical device products, expanding its product range in the in vitro diagnostic field [23] 分组7 - Hasa Lian has elected a new chairman and vice chairman for its board of directors [24] - Two-sided Needle's subsidiary plans to invest 68.8522 million yuan in a production base expansion project [25] - Sunshine Nuohe plans to transfer 70% of its controlling subsidiary's equity for 2 million yuan [26] 分组8 - Hengbang shares received an administrative regulatory decision from the Shandong Securities Regulatory Bureau for failing to complete the election of independent directors [27] - Huali shares plan to sign a related transaction contract worth approximately 59.2847 million yuan [28] - Shangwei shares plan to invest 520.4 million yuan to gain a controlling stake in Sichuan Zhongfu Taihua [30] 分组9 - Zejing Pharmaceutical's ZG006 has been included in the list of breakthrough therapeutic varieties for treating advanced neuroendocrine cancer [32] - Yaopi Glass's shareholder plans to reduce their stake by up to 2.26%, equating to a maximum of 21.1469 million shares [34] - Huate Gas has initiated a major lawsuit involving a claim of 180 million yuan [36] 分组10 - Zhongchumei's controlling shareholder plans to increase their stake by between 42 million and 80 million yuan [37] - Huitong shares' shareholder plans to reduce their stake by up to 1% [38] - Miaowei Exhibition plans to apply for an initial public offering of H shares on the Hong Kong Stock Exchange [40] 分组11 - Tianqi Lithium's subsidiary has appealed to the Chilean Supreme Court regarding a partnership agreement with SQM and Codelco [42] - Naxin Micro plans to repurchase shares worth between 200 million and 400 million yuan [44] - Pingao shares have reported significant uncertainty regarding future business development and profitability [46] 分组12 - Shunyu shares have been pre-selected for a project worth 1.023 billion yuan [48] - Zhongyuan Neipei plans to acquire a 2.5% share in an aerospace industry fund for 50 million yuan [50] - Huifa Food's shareholder plans to reduce their stake by up to 3%, equating to a maximum of 727.14 million shares [53] 分组13 - Junshi Biosciences' subcutaneous PD-1 new formulation has reached its primary endpoint in a Phase III clinical trial [54] - Industrial Fulian clarified that it has not lowered its fourth-quarter profit target amid market rumors [55] - Longpan Technology's subsidiary has signed a major supply agreement for lithium iron phosphate materials, significantly increasing the supply volume [56]

Group 1 - Core viewpoint: Huali Co., Ltd. announced a contract for equipment procurement and installation with its joint venture company, Xinjiang Herun Yiyuan, amounting to approximately 59.2847 million yuan, which will enhance the company's market competitiveness and business expansion [1][1][1] - The project involves a water plant in Xinjiang and operates under a DBFOT model with a 30-year concession [1][1][1] - The transaction is conducted at fair market prices, ensuring no benefit transfer or infringement of the company's interests, maintaining the company's independence [1][1][1] Group 2 - For the fiscal year 2024, Huali Co., Ltd.'s revenue composition is as follows: 81.66% from decorative composite materials manufacturing, 15.17% from smart water services, and 3.17% from other businesses [1][1][1] - As of the report date, Huali Co., Ltd. has a market capitalization of 4.7 billion yuan [1][1][1]

Core Viewpoint - Huali Co., Ltd. (603038.SH) aims to expand its smart water management business in Xinjiang by introducing ultrafiltration water treatment equipment and a smart water management software platform [1] Group 1: Business Expansion - The company’s membrane filtration division, Jiangsu Nuo Lai Smart Water Equipment Co., Ltd., plans to adopt a "joint venture + membrane filtration equipment sales" model to penetrate the Xinjiang market [1] - Jiangsu Nuo Lai has signed a contract with its joint venture partner, Xinjiang He Run Yi Yuan Water Treatment Technology Co., Ltd., for the procurement and installation of equipment [1] Group 2: Financial Details - The total contract amount for the equipment, technical services, and warranty services is tentatively set at 59.2847 million yuan [1]

证券代码：603038 证券简称：华立股份 公告编号：2025-066 东莞市华立实业股份有限公司 关于下属公司与关联方签订采购合同暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 为进一步开拓新疆地区智慧水务业务，实现超滤水处理装备及智慧 水务软件平台打入新疆市场。公司膜滤事业部下属公司江苏诺莱智慧水务装 备有限公司（以下简称"江苏诺莱"）拟采取"参股+膜滤装备销售"模式， 与其联营公司新疆河润忆源水处理科技有限公司（以下简称"新疆河润忆 源"）签署设备采购安装合同，新疆河润忆源拟向江苏诺莱采购合同设备、 技术服务和质保期服务，合同总金额暂定为 5,928.47 万元。 本次交易不构成重大关联交易，亦不构成《上市公司重大资产重组 管理办法》规定的重大资产重组。 本次关联交易已事先经公司独立董事专门会议和董事会审计委员会 审议通过后提交董事会审议通过。因本次关联交易金额未达到公司最近一期 经审计净资产绝对值 5%，无需提交股东会审议。 至本次关联交易为止，过去 12 个月内公司与新疆河润忆 ...

Core Viewpoint - The announcement by Huali Co., Ltd. regarding a contract for equipment procurement and installation with its joint venture company indicates a strategic move to enhance business expansion and market competitiveness [2] Group 1: Company Announcement - Huali Co., Ltd. announced that its membrane filtration division's subsidiary, Jiangsu Nuo Lai, plans to sign a contract with its joint venture company, Xinjiang He Run Yi Yuan, for equipment procurement and installation [2] - The total contract amount is tentatively set at 59.2847 million yuan [2] - This transaction does not constitute a major related party transaction and does not require shareholder approval [2] Group 2: Business Implications - The related party transaction is expected to aid in the company's business expansion [2] - The agreement is anticipated to further enhance the company's market competitiveness [2]

Core Viewpoint - Dongguan Huali Industrial Co., Ltd. is currently involved in a lawsuit concerning its subsidiary, Fujian Shangrun Investment Management Co., Ltd., which has been ruled against in a first-instance judgment, with the case amounting to approximately 60.72 million yuan [2][3][4]. Group 1: Lawsuit Details - The lawsuit is at the first-instance judgment stage, with Fujian Shangrun Investment Management Co., Ltd. as the defendant [2]. - The total amount involved in the lawsuit is 60.72 million yuan, along with related litigation costs [3]. - The lawsuit does not have a significant impact on the company's current or future profits, pending confirmation from the annual audit [3][7]. Group 2: Judgment Outcomes - The court ordered the defendant, Zibo Chuangfu No.1 Venture Capital Partnership, to pay 51.8 million yuan to the third party, Zibo Huali Shangrun Venture Capital Partnership, within ten days of the judgment [5][6]. - The defendant is also required to compensate for interest losses calculated based on the one-year Loan Prime Rate (LPR) from February 14, 2025, until actual payment [6]. - Fujian Shangrun Investment Management Co., Ltd. and other co-defendants are jointly liable for the debts specified in the judgment [6]. Group 3: Company Actions and Future Disclosures - The company will continue to monitor the lawsuit's progress and take necessary measures to protect its legal rights [7]. - The company commits to timely information disclosure based on the developments in the lawsuit [7].